HIV-1 and HIV-2 Antibody Confirmation and Differentiation, Plasma
Use
This test is used for the confirmation and differentiation of HIV-1 and HIV-2 antibodies in plasma specimens that show reactive results with third- and fourth-generation HIV serologic assays. It helps to confirm HIV infection and differentiate between HIV-1 and HIV-2, which is crucial for effective patient management and treatment planning.
Special Instructions
Not provided.
Limitations
A negative result for both HIV-1 and HIV-2 antibodies does not rule out acute HIV infection, as antibodies may not be detectable until 6 to 12 weeks following exposure. Results should be interpreted with caution in patients who have received the HIV-1 vaccine, as vaccine-specific antibodies may cross-react, yielding false-positive or indeterminate results. Assay performance is not established for heat-inactivated or cadaveric specimens and may be affected by hypergammaglobulinemic states, connective tissue disorders, or pregnancy.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Other)
Biomarkers
LOINC Codes
- 89365-1 - HIV 1 + 2 Ab Pnl SerPlBld IA.rapid
- 68961-2 - HIV1 Ab SerPlBld Ql IA.rapid
- 81641-3 - HIV 2 Ab SerPlBld Ql IA.rapid
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.8 mL
Container
Plastic vial
Collection Instructions
Centrifuge blood collection tube per manufacturer's instructions (e.g., within 2 hours for BD Vacutainer). Aliquot plasma into plastic vial.
Causes for Rejection
Presence of particulate matter, heat-inactivated specimens, and cadaveric specimens may lead to rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 6 days |
| Frozen | 30 days |